FINWIRES · TerminalLIVE
FINWIRES

Hengrui Pharma Wins China Regulator's Nod for Three Drugs

By

Jiangsu Hengrui Pharmaceuticals (SHA:600276, HKG:1276) has received market approval from China's National Medical Products Administration (NMPA) for its insulin sudelidec injection, according to a Wednesday filing to the Hong Kong stock exchange.

The company independently developed the Class 1 therapeutic biological product for treating adults with type 2 diabetes mellitus, with approvals granted for 3ml:300 units in both pre-filled injection pen and cartridge formats.

Additionally, the pharmaceutical firm secured regulatory acceptance for its drug marketing authorization application for Ruikang Luzetutamab for Injection (SHR-A2009), intended for adult patients with lung cancer that has progressed after epidermal growth factor receptor tyrosine kinase inhibitor therapy.

In a separate filing, Hengrui announced that its subsidiary, Fujian Shengdi Medicine, received NMPA approval to initiate a Phase II clinical trial for HRS5580 for Injection, a selective neurokinin-1 receptor antagonist designed to prevent postoperative nausea and vomiting.

Related Articles

Asia

Jinhui Signs Sale-and-Leaseback Deals for Two Bulk Carriers

Jinhui (HKG:0137) has entered into sale-and-leaseback arrangements for two bulk carriers under construction, according to a Tuesday Hong Kong bourse filing.The company will sell each vessel to a unit of ICBC Financial Leasing for up to $18 million and lease them back under separate five-year bareboat charter agreements.The vessels, each with a deadweight of about 64,500 metric tonnes, are expected to be delivered in February and March 2028.

HKG:0137
Asia

BOE Technology Controlling Shareholder to Boost Ownership

BOE Technology (SHE:000725) said its controlling shareholder, Beijing Electronics, plans to purchase company shares worth 500 million yuan to 1 billion yuan over the next six months, according to a Wednesday filing with the Shenzhen bourse.

SHE:000725
Asia

CapitaLand India Trust Spends 30% of Private Placement Proceeds

CapitaLand India Trust (SGX:CY6U) has used SG$45.6 million, representing 30.4% of the gross proceeds of the private placement conducted earlier this year, according to a Wednesday filing to the Singapore stock exchange.Of the SG$100 million earmarked to part fund the ongoing development and construction as part of its acquisition of Building 1 of Ebisu in Bangalore, India, the manager used SG$37.3 million.The company also used SG$5.7 million of the SG$47.4 million allotted to part fund the ongoing development and construction of and acquisition of an office project in Bangalore from Maia Estates Offices.It also used SG$2.6 million to pay all the fees and expenses tied to the private placement.The company's shares were up nearly 2% in recent trade.

SGX:CY6U